IntrinsicIntrinsic
← All summaries

Caribou Biosciences, Inc.

CRBU
Financials & Chart →

Business Summary

Caribou Biosciences, Inc. is a clinical-stage CRISPR genome-editing biopharmaceutical company focused on developing allogeneic CAR-T cell therapies for patients with devastating diseases . The company's core business model revolves around its novel chRDNA (CRISPR hybrid RNA-DNA) genome-editing technology, which is designed to enable more precise genome editing for allogeneic cell therapies . This technology allows for armoring strategies like checkpoint disruption and immune cloaking to enhance activity against hematologic malignancies . The company generates revenue through strategic collaborations and licensing arrangements related to its CRISPR intellectual property, in addition to potential future product sales .

Caribou Biosciences is advancing two clinical-stage allogeneic CAR-T cell therapy product candidates. The first, vispacabtagene regedleucel (vispa-cel, formerly CB-010), is an allogeneic anti-CD19 CAR-T cell therapy that has been evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL) in the ANTLER phase 1 clinical trial . Vispa-cel incorporates a PD-1 knockout to enhance potential for durable activity . The second candidate, CB-011, is an allogeneic anti-BCMA CAR-T cell therapy being evaluated in patients with relapsed or refractory multiple myeloma (r/r MM) in the CaMMouflage phase 1 clinical trial . CB-011 is designed with an immune cloaking approach, including the removal of the B2M protein and insertion of a B2M–HLA-E-peptide fusion, to reduce rapid immune-mediated rejection .

For the fiscal year ended December 31, 2025, Caribou Biosciences reported total revenue of $23.486 million , a decrease from $26.862 million in the prior year . The company incurred a net loss of $148.1 million in 2025 , compared to a net loss of $149.1 million in 2024 . The accumulated deficit as of December 31, 2025, was $596.5 million . Cash, cash equivalents, and marketable securities totaled $142.8 million as of December 31, 2025 . The filing does not provide specific figures for gross profit, gross margin percentage, operating income, operating margin, free cash flow, total debt, or net debt.

Year-over-year, total revenue decreased by $3.376 million, from $26.862 million in 2024 to $23.486 million in 2025 . The net loss slightly improved from $149.1 million in 2024 to $148.1 million in 2025 . The filing does not provide a detailed breakdown of revenue growth by segment or margin expansion/contraction.

In terms of significant operational developments, on April 24, 2025, Caribou Biosciences announced a strategic pipeline prioritization, which included discontinuing the GALLOP phase 1 trial of vispa-cel for lupus, discontinuing the AMpLify phase 1 clinical trial of CB-012 for r/r AML, and ceasing preclinical research . This prioritization also involved a workforce reduction of 47 employees, approximately 32% of the workforce . Concurrently, the Exclusive License Agreement with Memorial Sloan Kettering Cancer Center (MSKCC) was terminated, effective August 11, 2025 .

Business Outlook

Caribou Biosciences expects its cash, cash equivalents, and marketable securities of $142.8 million as of December 31, 2025, to be sufficient to fund its current operating plan through at least the next 12 months from the filing date of its consolidated financial statements . The company will require additional capital for the further development and commercialization of its product candidates, including potentially establishing its own internal manufacturing capabilities .

The company's primary growth area is the advancement of its vispa-cel product candidate. Based on ANTLER phase 1 clinical trial data, Caribou Biosciences is planning to conduct a randomized, controlled pivotal phase 3 clinical trial of vispa-cel in approximately 250 2L LBCL CD19-naïve patients who are ineligible for autologous stem cell transplant and autologous CAR-T cell therapy . Management believes there is a meaningful commercial opportunity within this population, as approximately 60% of the 12,000 2L LBCL patients treated annually in the United States are considered ineligible for autologous stem cell transplant and autologous CAR-T cell therapy . The primary endpoint for this trial would be progression-free survival (PFS), with an interim analysis planned . Secondary endpoints would include overall response rate (ORR), complete response (CR) rate, duration of response (DoR), duration of complete response (DoCR), overall survival, quality of life, and safety . The company is in ongoing engagement with the FDA regarding the design of this pivotal trial .

Another major growth vector is the continued development of CB-011. The dose expansion portion of the CaMMouflage phase 1 clinical trial for CB-011 in r/r MM patients was initiated in late 2025 . The recommended dose for expansion (RDE) has been determined as 450x10^6 viable CAR-T cells with a selected lymphodepletion regimen . This product candidate targets BCMA-positive malignancies and incorporates an immune cloaking approach to reduce rapid immune-mediated rejection .

The company expects its expenses to increase substantially as it progresses its clinical trials for vispa-cel and CB-011, particularly with the planned pivotal clinical trial for vispa-cel . This includes costs associated with hiring additional employees, acquiring or in-licensing intellectual property, expanding manufacturing capabilities, and seeking regulatory approvals . The company has optimized its manufacturing processes to produce sufficient cell yield for approximately 200-300 doses of vispa-cel and 50-100 doses for CB-011 per manufacturing run from a healthy donor . Caribou Biosciences expects to rely on CMOs for manufacturing its product candidates to expedite readiness for future clinical trials, and most of the CMOs currently contracted have demonstrated capabilities for commercial manufacturing . The company may also decide to build its own manufacturing facility or deploy a hybrid approach in the future .

Planned capital allocation includes continued investment in research and development, particularly for advancing vispa-cel and CB-011. The company's strategic pipeline prioritization in April 2025 involved discontinuing preclinical research to focus resources on these two clinical-stage candidates . The company has an at-the-market equity offering program and may utilize debt financings, new strategic collaborations, structured or other non-dilutive financings, or licensing arrangements to finance its cash needs .

Management explicitly flagged that the company currently does not have sufficient funds to conduct its planned pivotal clinical trial for vispa-cel and will need to raise additional funds to do so . If additional financing is not obtained, the company will be unable to initiate the planned pivotal clinical trial for vispa-cel or develop CB-011 beyond dose expansion . Furthermore, the company's expectation regarding the sufficiency of its existing capital resources is based on assumptions that may prove to be wrong, and available capital could be used sooner than expected .

Risk Factors

Caribou Biosciences faces several material risks, including significant operating losses since inception and the anticipation of continued losses for the foreseeable future, with an accumulated deficit of $596.5 million as of December 31, 2025 . The company will require substantial additional financing to conduct its planned pivotal clinical trial for vispa-cel and to implement operating plans, noting that it currently does not have sufficient funds for the vispa-cel pivotal trial and will be unable to develop CB-011 beyond dose expansion without additional financing . The regulatory landscape for gene and cell therapies is uncertain and evolving, with changes in regulatory requirements potentially leading to delays or discontinuation of product candidate development or unexpected costs . Competition in the biopharmaceutical industry, particularly in cell therapy and genome editing, is intense, with many competitors possessing substantially greater financial and technical resources . The company's intellectual property rights are subject to challenges, including third-party claims of infringement and administrative patent proceedings, which could impair its ability to commercialize product candidates or receive licensing revenue . Operational risks include the complexity of manufacturing product candidates, reliance on third-party suppliers and CMOs, and potential delays or difficulties in enrolling patients in clinical trials . Global economic conditions, including inflation, geopolitical tensions, and disruptions in the financial services industry, could adversely affect business operations, financial condition, and the ability to raise capital .

Management Priorities

Management's message to shareholders emphasizes the company's mission to develop innovative, transformative therapies for patients with devastating diseases through its novel CRISPR chRDNA genome-editing technology. The strategic priorities for the period ahead are centered on advancing the two clinical-stage allogeneic CAR-T cell therapy product candidates, vispa-cel and CB-011, for hematologic malignancies. This focus was underscored by the strategic pipeline prioritization on April 24, 2025, which involved discontinuing other preclinical and clinical programs and a workforce reduction of 47 employees, or approximately 32% of the workforce, to concentrate resources on vispa-cel and CB-011 . Management explicitly states that the company currently does not have sufficient funds to conduct its planned pivotal clinical trial for vispa-cel and will need to raise additional funds to do so . The company expects its cash, cash equivalents, and marketable securities of $142.8 million as of December 31, 2025, to be sufficient to fund its current operating plan through at least the next 12 months from the filing date .

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Overview
  2. [2] Item 1, Business — Overview
  3. [3] Item 1, Business — Overview
  4. [4] Item 1, Business — Our Strategy
  5. [5] Item 1, Business — Overview
  6. [6] Item 1, Business — Vispa-cel Overview: Strategy and Rationale
  7. [7] Item 1, Business — Overview
  8. [8] Item 1, Business — CB-011 Overview: Strategy and Rationale
  9. [9] Item 7, MD&A — Consolidated Results
  10. [10] Item 7, MD&A — Consolidated Results
  11. [11] Item 7, MD&A — Consolidated Results
  12. [12] Item 7, MD&A — Consolidated Results
  13. [13] Item 7, MD&A — Consolidated Results
  14. [14] Item 7, MD&A — Liquidity and Capital Resources
  15. [15] Item 7, MD&A — Consolidated Results
  16. [16] Item 7, MD&A — Consolidated Results
  17. [17] Item 1, Business — Overview
  18. [18] Item 1, Business — Overview
  19. [19] Item 1, Business — Overview
  20. [20] Item 7, MD&A — Liquidity and Capital Resources
  21. [21] Item 7, MD&A — Liquidity and Capital Resources
  22. [22] Item 1, Business — Planned Pivotal Phase 3 Clinical Trial in 2L r/r LBCL
  23. [23] Item 1, Business — Planned Pivotal Phase 3 Clinical Trial in 2L r/r LBCL
  24. [24] Item 1, Business — Planned Pivotal Phase 3 Clinical Trial in 2L r/r LBCL
  25. [25] Item 1, Business — Planned Pivotal Phase 3 Clinical Trial in 2L r/r LBCL
  26. [26] Item 1, Business — Planned Pivotal Phase 3 Clinical Trial in 2L r/r LBCL
  27. [27] Item 1, Business — CaMMouflage Phase 1 Clinical Trial for CB-011 in r/r MM
  28. [28] Item 1, Business — CaMMouflage Phase 1 Clinical Trial for CB-011 in r/r MM
  29. [29] Item 1, Business — CB-011 Overview: Strategy and Rationale
  30. [30] Item 1A, Risk Factors — Risks Relating to our Financial Position and Need for Additional Capital
  31. [31] Item 1A, Risk Factors — Risks Relating to our Financial Position and Need for Additional Capital
  32. [32] Item 1, Business — Manufacturing
  33. [33] Item 1, Business — Manufacturing
  34. [34] Item 1, Business — Manufacturing
  35. [35] Item 1, Business — Overview
  36. [36] Item 1A, Risk Factors — Raising additional capital may cause dilution to our stockholders, restrict our operations, and/or require us to relinquish rights to our genome-editing technologies or product candidates.
  37. [37] Item 1A, Risk Factors — We will need substantial additional financing to conduct our planned pivotal clinical trial for vispa-cel and to implement our operating plans. If we fail to obtain additional financing, we will be unable to complete the development and commercialization of our vispa-cel and/or CB-011 product candidates.
  38. [38] Item 1A, Risk Factors — We will need substantial additional financing to conduct our planned pivotal clinical trial for vispa-cel and to implement our operating plans. If we fail to obtain additional financing, we will be unable to complete the development and commercialization of our vispa-cel and/or CB-011 product candidates.
  39. [39] Item 1A, Risk Factors — We will need substantial additional financing to conduct our planned pivotal clinical trial for vispa-cel and to implement our operating plans. If we fail to obtain additional financing, we will be unable to complete the development and commercialization of our vispa-cel and/or CB-011 product candidates.
  40. [40] Item 1A, Risk Factors — We have incurred significant operating losses since our inception and anticipate that we will incur continued operating losses for the foreseeable future and we may not be able to achieve or sustain profitability.
  41. [41] Item 1A, Risk Factors — We will need substantial additional financing to conduct our planned pivotal clinical trial for vispa-cel and to implement our operating plans. If we fail to obtain additional financing, we will be unable to complete the development and commercialization of our vispa-cel and/or CB-011 product candidates.
  42. [42] Item 1A, Risk Factors — The regulatory landscape that will govern our product candidates is uncertain; regulations relating to more established gene therapy and cell therapy products are still developing, and changes in regulatory requirements could result in delays or discontinuation of development of our product candidates or unexpected costs in obtaining regulatory approval.
  43. [43] Item 1A, Risk Factors — We face significant competition from other biotechnology and pharmaceutical companies, which may result in other companies developing or commercializing products before, or more successfully than, we do, thus rendering our product candidates non-competitive or reducing the size of the market for our product candidates. Our operating results will suffer if we fail to compete effectively.
  44. [44] Item 1A, Risk Factors — If we do not possess the necessary intellectual property rights covering our CRISPR chRDNA genome-editing technology, our product candidates, or other proprietary technologies, we may not be able to block competitors or to compete effectively in the market.
  45. [45] Item 1A, Risk Factors — We rely on third parties to supply the materials for, and the manufacturing of, our clinical product candidates, and, if such product candidates receive regulatory approval, we may continue our reliance on third parties for manufacturing our commercial products. Our continued success is subject to the performance of these third parties.
  46. [46] Item 1A, Risk Factors — Unfavorable global economic conditions could adversely affect our business, financial condition, or results of operations.
  47. [47] Item 1, Business — Overview
  48. [48] Item 1A, Risk Factors — We will need substantial additional financing to conduct our planned pivotal clinical trial for vispa-cel and to implement our operating plans. If we fail to obtain additional financing, we will be unable to complete the development and commercialization of our vispa-cel and/or CB-011 product candidates.
  49. [49] Item 7, MD&A — Liquidity and Capital Resources

Analysis on 5/20/2026